Stockscreener 앱 받기
1.71
1.72%
-0.03
시장 영업 전:
1.75
0.04
+2.34%
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
Financial Metrics Exploration: Understanding SELLAS Life Sciences Group Inc (SLS) Through Ratios - DWinneX
Geode Capital Management LLC Purchases 128,355 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - Sete News
SELLAS Life Sciences Group Inc’s latest rating changes from various analysts - knoxdaily.com
SELLAS Life Sciences Group Inc (SLS) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Understanding the Risks of Investing in La Rosa Holdings Corp (LRHC) - knoxdaily.com
SELLAS reports promising AML treatment in preclinical study - Investing.com
SELLAS Life Sciences (SLS) Reports Promising Preclinical Results for SLS009 in Leukemia | SLS Stock News - GuruFocus
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference - The Manila Times
Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan
SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com
The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News
BILI Shares Experience Surge in Value - knoxdaily.com
SLSSellas Life Sciences Group Inc Latest Stock News & Market Updates - Stock Titan
Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World
Amazon's Earnings Could Fuel a Rapid Breakout - The Globe and Mail
SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire
Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com
Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com
Loop Capital analysts downgrades a Sell rating for Canadian National Railway Co (CNI) - knoxdaily.com
Analysts Are Recommending SELLAS Life Sciences Group Inc (SLS) As A Buy Candidate - Marketing Sentinel
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
SELLAS reports promising AML treatment trial results - Investing.com
SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha
Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener
Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq
SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire
Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan
Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World
Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha
Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq
SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView
SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz
SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Yet To Convince Analysts? - Stocksregister
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN
SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire
3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail
0.39%
3.66%
자본화:
|
볼륨(24시간):